# BioLineRx (BLRX) — Earnings

BLRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/blrx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.00 |
| EPS estimate | $0.00 |
| EPS surprise | +0.00% |
| Revenue surprise | −41.20% |
| Revenue | $294,000.00 |
| Revenue estimate | $500,000.00 |
| Reported | Aug 31, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1498403/000117891326004331/zk2635990.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/59478b06-4e36-185d-7901-ea1d06b39845.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 31, 2026 | $0.00 | $0.00 | 0.00% | $500,000.00 | $294,000.00 |
| Q1 2026 | May 27, 2026 | −$1.04 | $0.00 | 100.00% | $343,000.00 | $477,000.00 |
| Q4 2025 | Mar 23, 2026 | −$0.39 | −$0.27 | 29.87% | $514,000.00 | $514,000.00 |
| Q3 2025 | Nov 24, 2025 | −$0.67 | $0.00 | 100.00% | $990,000.00 | $427,000.00 |
| Q2 2025 | Aug 14, 2025 | −$0.35 | $0.00 | 100.00% | $661,333.00 | $304,000.00 |
| Q1 2025 | May 27, 2025 | −$0.95 | $0.00 | 100.00% | $1.5M | $255,000.00 |
| Q4 2024 | Mar 31, 2025 | −$0.81 | −$1.60 | -98.19% | $7.7M | $11.7M |
| Q3 2024 | Nov 25, 2024 | −$1.74 | $0.00 | 100.00% | $5.3M | $4.9M |
| Q2 2024 | Aug 15, 2024 | −$3.02 | $0.00 | 100.00% | $3.9M | $5.4M |
| Q1 2024 | May 28, 2024 | −$11.66 | $0.00 | 100.00% | $340,000.00 | $6.9M |
| Q4 2023 | Mar 26, 2024 | −$8.84 | −$7.64 | 13.64% | $150,000.00 | $4.8M |
| Q3 2023 | Nov 20, 2023 | −$8.44 | −$12.00 | -42.15% | — | — |
| Q2 2023 | Aug 30, 2023 | −$6.83 | −$12.00 | -75.59% | — | — |
| Q1 2023 | May 24, 2023 | −$5.63 | −$6.00 | -6.61% | — | — |
| Q4 2022 | Mar 22, 2023 | −$5.43 | −$3.62 | 33.33% | — | — |
| Q3 2022 | Nov 15, 2022 | −$6.63 | −$6.00 | 9.54% | — | — |
| Q2 2022 | Aug 16, 2022 | −$5.23 | −$6.00 | -14.81% | — | — |
| Q1 2022 | May 11, 2022 | −$6.03 | −$6.00 | 0.50% | — | — |
| Q4 2021 | Mar 16, 2022 | −$5.63 | $0.00 | 100.00% | — | — |
| Q3 2021 | Nov 18, 2021 | −$5.03 | −$6.00 | -19.40% | — | — |

## Frequently Asked Questions

### When did BioLineRx (BLRX) last report earnings?

BioLineRx last reported on Aug 31, 2026, covering fiscal Q2 2026.

### Did BLRX beat earnings estimates?

BioLineRx reported EPS of $0.00 for Q2 2026, in line with the $0.00 consensus estimate.

### How much revenue did BLRX report last quarter?

BioLineRx reported $294,000.00 in revenue for Q2 2026, against a consensus estimate of $500,000.00.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).